Core Insights - The Hong Kong stock market welcomed two pharmaceutical companies, Heng Rui Pharmaceutical and MIRXES-B, on May 23, with both stocks experiencing significant price increases on their debut [2] - MIRXES, despite being less well-known, saw its stock price rise over 30% by the time of reporting, achieving a market capitalization exceeding HKD 8 billion [2] - MIRXES successfully raised HKD 880.5 million through the issuance of 46.62 million shares at HKD 23.30 each, with a subscription rate of 25.51 times for the public offering [2][3] Company Overview - MIRXES, founded in 2014 and headquartered in Singapore, specializes in microRNA (miRNA) technology, focusing on disease screening and diagnostic solutions in key Asian markets, including Singapore and China [3] - The company has one core product, GASTROClear™, and two other commercialized products, LUNGClear™ and Fortitude™, along with six candidates in preclinical stages [3][4] Product Details - GASTROClear™ is a blood-based miRNA diagnostic test for gastric cancer screening, consisting of 12 miRNA biomarkers. It was the first and only molecular diagnostic IVD product approved for gastric cancer screening globally [4] - The product received a breakthrough medical device designation from the FDA in May 2023, marking a significant achievement for MIRXES in the miRNA diagnostic field [4] Financial Performance - MIRXES reported revenues of USD 17.76 million, USD 24.19 million, and USD 20.28 million for the years 2022, 2023, and 2024, respectively, with gross profits of USD 9.33 million, USD 13.58 million, and USD 8.89 million [4] - The company is projected to incur losses of USD 56.20 million, USD 69.57 million, and USD 92.21 million over the same period [4] Fund Utilization - The funds raised from the global offering will be allocated to the research and development of GASTROClear™, regulatory filings, production, commercialization, and enhancing the company's end-to-end capabilities, as well as general operational expenses [5]

Group 1 - MIRXES-B was listed on the Hong Kong Stock Exchange with an issue price of HKD 23.3 per share, raising approximately HKD 881 million from the issuance of 46.62 million shares [1] - The stock price increased by 27.90% to HKD 29.80, resulting in a market capitalization exceeding HKD 8.235 billion [1] - The company plans to apply for a dual listing on the Singapore Stock Exchange after its global offering, aiming to enhance its reach in Southeast Asia and mainland China [1][2] Group 2 - MIRXES was founded in 2014 and is headquartered in Singapore, specializing in microRNA technology [2] - The company's core product, GASTROClear, is the world's first and only approved molecular diagnostic IVD product for gastric cancer screening [2] - The CEO mentioned that the company is in the early stages of commercialization and is effectively controlling costs through automation [2]

Company News - Xiaomi Group (01810.HK) launched its flagship processor, the玄戒O1, utilizing second-generation 3nm advanced process technology, which will be featured in the 15S Pro, Tablet 7 Ultra, and Watch S4 [1] - Heng Rui Pharmaceutical (01276.HK) saw its shares open over 27% higher in the dark market yesterday, closing up 32.24% at HKD 58.25, with a trading volume of HKD 751 million [1] - New China Life Insurance (01336.HK) invested HKD 10 billion to subscribe to the second phase of the Guofeng Xinghua Honghu Zhiyuan private securities investment fund [1] - BOSS Zhipin (02076.HK) reported total revenue of RMB 1.923 billion for the year ending March 31, 2025, a year-on-year increase of 12.88%, with net profit attributable to shareholders at RMB 518 million, up 111.53% year-on-year [1] - AIA Group (01299.HK) repurchased 325,000 shares at a cost of HKD 21.2 million on May 22 [1] - Mirxes-B (02629.HK), a Singapore-based microRNA technology company, debuted today, with its shares rising over 40% during the dark market trading period yesterday [1] Industry News - HSBC Holdings (00005.HK) repurchased 1.6 million shares at a cost of HKD 152.2 million on May 21, and spent GBP 32.8 million to repurchase a total of 3.7 million shares on other exchanges [2] - China Health Group (00673.HK) announced that its shares will resume trading at 9:00 AM today [2] - Country Garden (02007.HK) reportedly received support from nearly 75% of bondholders for its debt restructuring plan [2]

Core Viewpoint - The recent IPOs in the Hong Kong stock market have shown strong profitability, with significant price increases for newly listed stocks like 恒瑞医药 (Hengrui Medicine) and MIRXES-B during the dark pool trading period [1][2]. Company Summaries 恒瑞医药 (Hengrui Medicine) - 恒瑞医药, an established A-share company listed since 2000, has a strong focus on R&D, with a projected R&D expenditure of 29.4% of total revenue in 2024 [6]. - The company has returned approximately RMB 80.29 billion in cash dividends to shareholders since its A-share listing, which is 16.8 times the capital raised at that time [6]. - 恒瑞医药 has 19 marketed innovative drugs and over 90 new molecular entities in clinical or later stages of development [6]. - The total revenue for 恒瑞医药 is projected to be RMB 28 billion in 2024, with a compound annual growth rate (CAGR) of about 14% since 2014, significantly outpacing the global pharmaceutical market's CAGR of approximately 4% [6]. - The revenue contribution from innovative drugs increased from 38.1% in 2022 to 43.4% in 2023, and is expected to reach 46.3% in 2024, while the contribution from generic drugs decreased from 60.3% in 2022 to 42.0% in 2024 [7]. MIRXES-B - MIRXES-B, founded in 2014 and based in Singapore, specializes in microRNA technology for disease screening and diagnostics, particularly in cancer detection [7]. - The company is one of the few globally to have received regulatory approval for molecular cancer screening IVD products, and is the first to receive such approval for molecular gastric cancer screening [7]. - Despite its innovative offerings, MIRXES-B is currently operating at a loss, with losses increasing from USD 0.56 million in 2022 to USD 0.696 million in 2023, and projected losses of USD 0.92 million in 2024 [7]. - The subscription multiple for MIRXES-B is significantly lower than that of 恒瑞医药, with 25 times compared to 恒瑞医药's 409 times [7]. Market Trends - The recent trend in the Hong Kong IPO market shows a strong upward movement, with only 6 out of 23 newly listed companies this year experiencing a decline on their first trading day, while others have seen substantial gains [8].

Core Viewpoint - The article highlights the significant price increases of two new stocks, 恒瑞医药 (Hengrui Medicine) and MIRXES-B, during the dark trading period before their listing on the Hong Kong stock market, indicating strong market interest and potential investment opportunities. Group 1: Hengrui Medicine - Hengrui Medicine, a well-established A-share company listed since 2000, has a strong focus on R&D, with a projected R&D investment of 29.4% of total revenue in 2024 [3] - The company has a diverse portfolio with 19 marketed innovative drugs and over 90 in clinical or later stages of development [4] - Hengrui's total revenue is expected to reach RMB 28 billion in 2024, with a compound annual growth rate (CAGR) of approximately 14% since 2014, significantly outpacing the global pharmaceutical market's CAGR of about 4% [4] - The sales revenue from innovative drugs has increased from 38.1% of total revenue in 2022 to 43.4% in 2023, and is projected to reach 46.3% in 2024, while sales from generic drugs are decreasing [4] Group 2: MIRXES-B - MIRXES-B, founded in 2014 and based in Singapore, specializes in miRNA technology for disease screening and diagnostics, particularly in cancer detection [4] - The company is one of the few globally to have received regulatory approval for its molecular cancer screening IVD products, including the first approval for molecular gastric cancer screening [4] - Despite its innovative offerings, MIRXES-B is currently operating at a loss, with losses increasing from USD 0.56 million in 2022 to USD 0.696 million in 2023, and projected losses of USD 0.92 million in 2024 [5] - The subscription ratio for MIRXES-B is significantly lower than that of Hengrui Medicine, with 25 times compared to Hengrui's 409 times [6]

Major Events - Heng Rui Medicine (01276) plans to globally issue 224.5 million H-shares, expected to be listed on May 23 [1] - MIRXES-B (02629) will conduct an IPO from May 15 to May 20, aiming to globally issue 46.62 million shares [1] - Green Tea Group (06831) received 317.54 times subscription for its public offering in Hong Kong, with a final issue price of HKD 7.19 per share [1] - CSPC Pharmaceutical Group (01093) signed an exclusive licensing agreement with Cipla for the commercialization of Irinotecan Liposome Injection in the United States [1] - CanSino Biologics (06185) received clinical trial approval for its inhaled tuberculosis booster vaccine in Indonesia [1] - Fuhong Hanlin (02696) has been included in the MSCI Global Small Cap Index [1] - Financial One Account (06638) received a privatization offer from Ping An Group (02318) at a premium of approximately 23.10% [1] Financial Reports - Alibaba-W (09988) reported revenue and net profit growth for the fiscal year 2025, with net profit attributable to shareholders increasing by 62% to CNY 129.47 billion [1] - NetEase-S (09999) announced Q1 results with net profit attributable to shareholders at CNY 10.301 billion, a year-on-year increase of 34.94%, and a quarterly dividend of USD 0.135 per share [1] - Geely Automobile (00175) released Q1 results showing a significant increase in profit attributable to shareholders of CNY 5.672 billion, up 263.59% year-on-year [1] - Beike-W (02423) reported a total transaction volume growth of 34.0% year-on-year in Q1, with net revenue increasing by 42.4% [1] - Minhua Holdings (01999) announced annual results with profit attributable to shareholders of HKD 2.063 billion, a decrease of 10.41% year-on-year [1] - Shoucheng Holdings (00697) reported Q1 results with profit attributable to shareholders of HKD 213 million, an increase of 80.5% year-on-year [1] - Fourth Paradigm (06682) showed strong performance in core business with total revenue of CNY 1.077 billion in Q1, a year-on-year growth of 30.1% [1]